EBERS
Develops and manufactures advanced bioreactors and culture chambers for 3D cell culture and tissue engineering research, enabling precise mechanical and flow stimulation of scaffolds.
- CEO / Founder
- Pedro Moreo
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $2.6M
- Latest Round
- Grant
- Key Investors
- European Commission
Technology & Products
Key Products
EBERS specializes in advanced bioreactors for 3D cell culture and tissue engineering, including systems for mechanical and flow stimulation. They also offer CE-marked clinical devices for organ preservation, such as the ARK Kidney for renal and hepatic ex-situ normothermic perfusion.
Technological Advantage
Proprietary bioreactor designs that apply controlled flow rates and direct deformation to scaffolds, simulating in-vivo conditions; verified through academic collaborations and clinical certifications (CE mark under EU MDR 2017/745). Advantage is defensible through design expertise and regulatory approvals.
Differentiation
Value Proposition
Provides researchers with automated, customizable systems that replicate in-vivo mechanical and flow conditions, accelerating tissue engineering experiments and improving protocol reliability while reducing manual intervention.
How They Differentiate
Specializes in bioreactors for mechanical and flow stimulation in 3D cell culture, unlike general bioprinting hardware companies; offers CE-marked clinical devices for organ preservation, providing a regulatory edge in medical applications.
Market & Competition
Target Customers
Academic research institutions, biotechnology companies, and medical device developers in regenerative medicine and tissue engineering
Industry Verticals
Biotechnology; Medical Research; Regenerative Medicine; Tissue Engineering
Competitors
Paragonix Technologies, Organ Recovery Systems Inc., OrganOx Ltd.
Growth & Milestones
Growth Metrics
Awarded €2.6M SME-Phase II grant from European Commission for certification and clinical validation of organ preservation device; expanded distribution to UK, Australia, Germany, Switzerland, Japan via partnerships.
Major Milestones
Founded in 2009 as spin-off from University of Zaragoza; ISO13485 certification obtained; CE mark certification for ARK Kidney® under EU MDR 2017/745 in 2023; €2.6M European Commission SME-Phase II grant awarded; Distribution agreements with Don Whitley Scientific and AR Brown Co., Ltd.
Notable Customers
HypOxygen (United States of America), Meintrup DWS Laborgerate GmbH (Germany)